NICE recommends off-label preventative breast cancer treatments
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, is recommending that tamoxifen or raloxifene should be used to prevent breast cancer in certain women and that more patients should be eligible for genetic testing.